Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
For patients with NK/T-cell lymphoma, plasma EBV-DNA has been found to be a prognostic
factor, and those with positive plasma EBV-DNA at the end of treatments are more likely to
suffer from disease relapse. Thus, this study aims to evaluate the role of maintenance with
anti-PD-1 antibody.